Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)

Circulation

Volumn 102, Issue 15, 2000, Pages 1748-1754

  Teo, Koon K ^a,d,e,i   Burton, Jeffrey R ^a,d   Buller, Christopher E ^b   Plante, Sylvain ^c   Catellier, Diane ^d,f   Tymchak, Wayne ^a,d   Dzavik, Vladimir ^a,d   Taylor, Dylan ^a,d   Yokoyama, Shinji ^a,g   Montague, Terrence J ^a,d,h  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^h MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

ⁱ MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Cholesterol; Coronary disease

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034633814     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.15.1748     Document Type: Article

References (24)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
6. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial
7. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
8. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
9. Distribution of lipids in 8500 men with coronary artery disease
10. Range of serum cholesterol values in the population developing coronary artery disease
11. Effect of coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients
12. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
13. Mechanism of protective effects of ACE inhibition on coronary artery disease
14. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
15. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
16. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
17. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
18. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc committee for Grading of Coronary Artery Disease, Council of Cardiovascular Surgery, American Heart Association
19. Assessment of short-, medium- and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms
20. Random effects models for longitudinal data
21. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
22. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study
23. Studies of left ventricular dysfunction (SOLVD) sugbroup results
24. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)